[Basic results of the multicenter trial NOKTURN]

Integration of noliprel treatment of arterial hypertension with educational programs on correction of associated risk factors in outpatient practice for reduction of the overall cardiovascular risk.

An open, multicenter, non-comparative trial with participation of 140 physicians from 14 regions of Russia comprised 1195 patients aged 30-65 years with mild-to-moderate hypertension (SBP = 140-179 mmHg, and/or DBP = 90-109 mm Hg) who had never received regular antihypertensive therapy. This one-year study had an active 3-month stage and follow-up stage for 9 months.

Noliprel significantly decreased both systolic and diastolic blood pressure. The response to the treatment was achieved in 95.6% patients, the target blood pressure was achieved in 76.2% patients. A mean level of total cholesterol lowered from 5.5 +/- 1.0 mmol/l to 5.1 +/- 0.8 mmol/l (p < 0.001), body mass index--from 28.4 +/- 4.5 to 27.2 +/- 4.3 (p < 0.001). Hypercholesterolemia occurred before the study in 65.5% patients, at the end of the study--in 49.2%, obesity was registered in 79 and 70.2%, smoking in 21.6 and 14.6%, respectively. The mean overall risk to develop fatal cardiovascular events reduced from 2.5 +/- 3.6% at initiation of the study to 1.3 +/- 1.8% in the end of the study (p < 0.001).

The integration of medication with noliprel and training program successfully lowered overall risk to develop fatal outcomes of cardiovascular diseases in primary health care service.